Guardant Health’s (GH) “Outperform” Rating Reaffirmed at William Blair

Share on StockTwits

William Blair reiterated their outperform rating on shares of Guardant Health (NASDAQ:GH) in a report published on Wednesday morning.

Several other equities analysts have also recently issued reports on the company. Bank of America reissued a neutral rating and issued a $60.00 price objective (up previously from $42.00) on shares of Guardant Health in a report on Thursday, February 28th. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $42.00 to $85.00 and gave the company an overweight rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $72.50.

Guardant Health stock opened at $94.45 on Wednesday. The stock has a market cap of $6.35 billion and a price-to-earnings ratio of -33.73. Guardant Health has a fifty-two week low of $27.04 and a fifty-two week high of $98.25.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.05. The firm had revenue of $32.87 million for the quarter, compared to analysts’ expectations of $24.57 million. As a group, equities research analysts forecast that Guardant Health will post -1.26 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pendal Group Ltd purchased a new stake in shares of Guardant Health in the fourth quarter worth $213,000. Emerald Advisers LLC purchased a new stake in shares of Guardant Health in the fourth quarter worth $752,000. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Guardant Health in the fourth quarter worth $2,096,000. Rhumbline Advisers purchased a new stake in shares of Guardant Health in the fourth quarter worth $747,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Guardant Health in the fourth quarter worth $26,000. 69.54% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analyzing Webster Financial  & Cadence Bancorp
Analyzing Webster Financial & Cadence Bancorp
Financial Analysis: CIBT Education Group  versus OneSmart International Edun Gr
Financial Analysis: CIBT Education Group versus OneSmart International Edun Gr
Metropolitan Life Insurance Co. NY Has $130,000 Stake in PC Connection, Inc.
Metropolitan Life Insurance Co. NY Has $130,000 Stake in PC Connection, Inc.
Metropolitan Life Insurance Co. NY Grows Holdings in PetIQ Inc
Metropolitan Life Insurance Co. NY Grows Holdings in PetIQ Inc
MetLife Investment Advisors LLC Has $209,000 Stake in Calix Inc
MetLife Investment Advisors LLC Has $209,000 Stake in Calix Inc
MetLife Investment Advisors LLC Has $214,000 Holdings in RadNet Inc.
MetLife Investment Advisors LLC Has $214,000 Holdings in RadNet Inc.


 
© 2006-2019 Zolmax.